Schizophrenia relapse, patient considerations, and potential role of lurasidone

References

• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• WiersmaDNienhuisFJSlooffCJGielRNatural course of schizophrenic disorders: a 15-year follow up of a Dutch incidence cohortSchizophr Bull199824175859502547
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
   PubMed Web of Science ®Google Scholar
• MuenchJHamerAMAdverse effects of antipsychotic medicationsAm Fam Physician201081561762220187598
   PubMed Web of Science ®Google Scholar
• BruijnzeelDSuryadevaraUTandonRAntipsychotic treatment of schizophrenia: an updateAsian J Psychiatr2014113725216917
   PubMedGoogle Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• CitromeLA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approachCNS Drugs2013271187991124062193
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-makingExpert Opin Pharmacother200910121917192819558339
   PubMed Web of Science ®Google Scholar
• LoebelACitromeLLurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depressionBJPsych Bull201539523724126755968
   PubMed Web of Science ®Google Scholar
• CitromeLCucchiaroJSarmaKLong-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled studyInt Clin Psychopharmacol201227316517622395527
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJXuJSarmaKPikalovAKaneJMEffectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority studySchizophr Res201314719510223583011
   PubMed Web of Science ®Google Scholar
• TandonRCucchiaroJPhillipsDA double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophreniaJ Psychopharmacol2016301697726645209
   PubMed Web of Science ®Google Scholar
• RajagopalanKO’DayKMeyerKPikalovALoebelAAnnual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-releaseJ Med Econ201316898799623742620
   PubMedGoogle Scholar
• LoebelACucchiaroJSarmaKEfficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trialSchizophr Res20131451–310110923415311
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• HarveyPDSiuCOOgasaMLoebelAEffect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation studySchizophr Res20151661–333433826117157
   PubMed Web of Science ®Google Scholar
• HarveyPDSiuCOHsuJCucchiaroJMaruffPLoebelAEffect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extensionEur Neuropsychopharmacol201323111373138224035633
   PubMed Web of Science ®Google Scholar
• LoebelACitromeLCorrellCUXuJCucchiaroJKaneJMTreatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalationBMC Psychiatry20151527126521019
   PubMed Web of Science ®Google Scholar
• LoebelASilvaRGoldmanRLurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled studyJ Clin Psychiatry2016719 Epub ahead of print
   Web of Science ®Google Scholar
• PigottTACarsonWHSahaARAripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week studyJ Clin Psychiatry20036491048105614628980
   PubMed Web of Science ®Google Scholar
• KaneJMMackleMSnow-AdamiLZhaoJSzegediAPanagidesJA randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatmentJ Clin Psychiatry201172334935521367356
   PubMed Web of Science ®Google Scholar
• FleischhackerWWHobartMOuyangJBrexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: randomized, double-blind, placebo-controlled studyEur Neuropsychopharmacol201525Suppl 2S527
   Web of Science ®Google Scholar
• DurgamSEarleyWLiRLong-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trialSchizophr Res2016714 Epub ahead of print
   Web of Science ®Google Scholar
• WeidenPJManningRWolfgangCDA randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE studyCNS Drugs Epub752016
   Web of Science ®Google Scholar
• BeasleyCMJrSuttonVKHamiltonSHA double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapseJ Clin Psychopharmacol200323658259414624189
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200727161417224706
   PubMed Web of Science ®Google Scholar
• PeuskensJTrivediJMalyarovSPrevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patientsPsychiatry (Edgmont)2007411345020428302
   PubMedGoogle Scholar
• AratoMO’ConnorRMeltzerHYZEUS Study GroupA 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) studyInt Clin Psychopharmacol200217520721512177583
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKHeresSKisslingWDavisJMMaintenance treatment with antipsychotic drugs for schizophreniaCochrane Database Syst Rev20125CD00801622592725
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• CorrellCUCucchiaroJSilvaRHsuJPikalovALoebelALong-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension studyCNS Spectr Epub462016
   Web of Science ®Google Scholar
• CitromeLWeidenPJMcEvoyJPEffectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension studyCNS Spectr201419433033924330868
   PubMed Web of Science ®Google Scholar
• StahlSMCucchiaroJSimonelliDHsuJPikalovALoebelAEffectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension studyJ Clin Psychiatry201374550751523541189
   PubMed Web of Science ®Google Scholar
• MeyerJMMaoYPikalovACucchiaroJLoebelAWeight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophreniaInt Clin Psychopharmacol201530634235026196189
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clin Schizophr Relat Psychoses201262768522776634
   PubMedGoogle Scholar
• CitromeLKetterTACucchiaroJLoebelAClinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmedJ Affect Disord2014155202724246116
   PubMed Web of Science ®Google Scholar
• KetterTASarmaKSilvaRKrogerHCucchiaroJLoebelALurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension studyDepress Anxiety201633542443426918425
   PubMed Web of Science ®Google Scholar
• CitromeLBlondeLDamatarcaCMetabolic issues in patients with severe mental illnessSouth Med J200598771472016108240
   PubMed Web of Science ®Google Scholar
• DibonaventuraMGabrielSDupclayLGuptaSKimEA patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaBMC Psychiatry2012122022433036
   PubMed Web of Science ®Google Scholar
• AwadGHassanMLoebelAHsuJPikalovARajagopalanKHealth-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophreniaBMC Psychiatry2014145324559217
   PubMed Web of Science ®Google Scholar
• AwadGNg-MakDRajagopalanKHsuJPikalovALoebelALong-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophreniaBMC Psychiatry20161617627245981
   PubMed Web of Science ®Google Scholar
• McEvoyJPCitromeLHernandezDEffectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label studyJ Clin Psychiatry201374217017923473350
   PubMed Web of Science ®Google Scholar
• CitromeLEramoAFrancoisCLack of tolerable treatment options for patients with schizophreniaNeuropsychiatr Dis Treat2015113095310426719694
   PubMed Web of Science ®Google Scholar
• CitromeLNew second-generation long-acting injectable antipsychotics for the treatment of schizophreniaExpert Rev Neurother201313776778323898849
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJXuJSarmaKPikalovAKaneJMEffectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind studyPoster presented at: American Psychiatric Association Annual MeetingMay 5–9, 2012Philadelphia, PA, USA
   Google Scholar